Published in J Infect Dis on June 01, 2005
Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med (2006) 1.56
Independent effects of nevirapine prophylaxis and HIV-1 RNA suppression in breast milk on early perinatal HIV-1 transmission. J Acquir Immune Defic Syndr (2007) 0.91
Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis (2005) 3.91
Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis (2005) 3.59
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis (2005) 2.54
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51
The challenge of HIV-1 subtype diversity. N Engl J Med (2008) 3.88
HIV vaccine research: the way forward. Science (2008) 3.86
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Combining Google Earth and GIS mapping technologies in a dengue surveillance system for developing countries. Int J Health Geogr (2009) 2.87
Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis (2009) 2.75
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. J Infect Dis (2010) 2.15
Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. J Infect Dis (2002) 1.70
Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis (2011) 1.55
Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother (2003) 1.53
Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. Clin Infect Dis (2004) 1.52
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis (2003) 1.51
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J Acquir Immune Defic Syndr (2004) 1.48
HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388. Clin Infect Dis (2004) 1.39
What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J Infect Dis (2003) 1.38
Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother (2004) 1.34
Ebola and quarantine. N Engl J Med (2014) 1.32
The challenge of HIV-1 subtype diversity. N Engl J Med (2008) 1.28
Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab (2009) 1.16
Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. J Infect Dis (2004) 1.12
Antiretroviral treatment as prevention. N Engl J Med (2011) 1.12
A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. Stat Commun Infect Dis (2011) 1.06
Acceptability of male circumcision for the prevention of HIV among high-risk heterosexual men in Thailand. Sex Transm Dis (2010) 1.05
Advances in antiretroviral therapy. Top HIV Med (2007) 1.05
Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PLoS One (2011) 1.04
Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand. AIDS Res Hum Retroviruses (2009) 1.02
Patents versus patients? Antiretroviral therapy in India. N Engl J Med (2005) 0.95
Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (2003) 0.95
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med (2009) 0.93
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS Res Hum Retroviruses (2010) 0.93
Lessons drawn from recent HIV vaccine efficacy trials. J Acquir Immune Defic Syndr (2010) 0.92
Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment. HIV Clin Trials (2013) 0.91
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS (2002) 0.89
Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter. J Clin Microbiol (2002) 0.87
In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities. AIDS Res Hum Retroviruses (2013) 0.87
Patterns of geographic mobility predict barriers to engagement in HIV care and antiretroviral treatment adherence. AIDS Patient Care STDS (2014) 0.86
CROI 2013: Advances in antiretroviral therapy. Top Antivir Med (2013) 0.85
Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther (2006) 0.84
Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature. AIDS Res Hum Retroviruses (2011) 0.83
Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin Pharmacol Ther (2002) 0.83
Advances in antiretroviral therapy. Top HIV Med (2010) 0.82
The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART. J Med Virol (2009) 0.82
207-nm UV light - a promising tool for safe low-cost reduction of surgical site infections. I: in vitro studies. PLoS One (2013) 0.81
Poor agreement between 2 assays for measuring low levels of HIV-1 viral load. Clin Infect Dis (2009) 0.80
Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. J Acquir Immune Defic Syndr (2016) 0.80
Advances in antiretroviral therapy. Top Antivir Med (2012) 0.79
Advances in antiretroviral therapy. Top HIV Med (2009) 0.78
Translational research insights from completed HIV vaccine efficacy trials. J Acquir Immune Defic Syndr (2013) 0.78
Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapy. Top HIV Med (2008) 0.77
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel. Top HIV Med (2003) 0.76
Advances in antiretroviral therapy. Top HIV Med (2005) 0.75
Advances in antiretroviral therapy. Top HIV Med (2006) 0.75
Advances in antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA. Top HIV Med (2004) 0.75
Preventing HIV-1 Infection in Women using Oral Pre-Exposure Prophylaxis: A Meta-analysis of Current Evidence. J Acquir Immune Defic Syndr (2016) 0.75
Advances in antiretroviral therapy. Top HIV Med (2003) 0.75
Advances in antiretroviral therapy. Top Antivir Med (2011) 0.75